Beryl Drugs Ltd
Beryl Drugs Ltd (BERLDRG) last traded at ₹23, a market capitalisation of ₹11.6 crore, on a P/E of 18.8. Over the past 52 weeks the stock has ranged between ₹15.9 and ₹30. Beryl Drugs Ltd last reported results for the quarter ended Jun 2026, with sales of ₹7.57 crore and net profit of ₹0.22 crore. Figures are as of 25 Aug 2026 and are not real time.
Beryl Drugs Ltd share price and key metrics
Metrics as of 25 Aug 2026. Not real time.
Beryl Drugs Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹7.57 cr, up 56.7% from ₹4.83 cr a year earlier. Net profit was ₹0.22 cr, up 1000.0% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 5.64 | 5.4 | 5.22 | 4.83 | 5.16 | 3.85 | 5.47 | 7.57 |
| Expenses | 5.08 | 4.81 | 4.72 | 4.28 | 4.43 | 4.05 | 4.13 | 6.92 |
| Operating profit | 0.56 | 0.59 | 0.5 | 0.55 | 0.73 | -0.2 | 1.34 | 0.65 |
| OPM % | 9.93% | 10.93% | 9.58% | 11.39% | 14.15% | -5.19% | 24.50% | 8.59% |
| Other income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest | 0.12 | 0.12 | 0.08 | 0.1 | 0.08 | 0.09 | 0.07 | 0.06 |
| Depreciation | 0.33 | 0.31 | 0.32 | 0.38 | 0.39 | 0.32 | 0.4 | 0.32 |
| Profit before tax | 0.11 | 0.16 | 0.1 | 0.07 | 0.26 | -0.61 | 0.87 | 0.27 |
| Tax % | 90.91% | 62.50% | -50.00% | 71.43% | 96.15% | -72.13% | 34.48% | 18.52% |
| Net profit | 0.01 | 0.05 | 0.15 | 0.02 | 0.01 | -0.17 | 0.56 | 0.22 |
| EPS (₹) | 0.02 | 0.10 | 0.30 | 0.04 | 0.02 | -0.34 | 1.10 | 0.43 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Beryl Drugs Ltd annual results
| ₹ crore | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|
| Sales | 14.03 | 14.48 | 26.84 | 26.73 | 21.15 | 19.31 | 22.05 |
| Operating profit | 1.45 | 0.44 | 2 | 2.28 | 1.24 | 2.42 | 2.52 |
| OPM % | 10.33% | 3.04% | 7.45% | 8.53% | 5.86% | 12.53% | 11.43% |
| Net profit | 0.24 | -0.66 | 0.77 | 0.77 | 0.58 | 0.42 | 0.62 |
| EPS (₹) | 0.47 | -1.30 | 1.52 | 1.52 | 1.14 | 0.83 | 1.21 |
TTM is the trailing twelve months to the most recent quarter.
Beryl Drugs Ltd growth and returns
- 10 Years
- 4%
- 5 Years
- 7%
- 3 Years
- -10%
- TTM
- 5%
- 10 Years
- 9%
- 5 Years
- 44%
- 3 Years
- -18%
- TTM
- 170%
- 10 Years
- 3%
- 5 Years
- 15%
- 3 Years
- 4%
- 1 Year
- -1%
- 10 Years
- 3%
- 5 Years
- 4%
- 3 Years
- 6%
- Last Year
- 4%
Beryl Drugs Ltd shareholding pattern
Promoters held 27.82% at Jun 2026, up from 26.38% at Jun 2025.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 26.38% | 26.38% | 26.38% | 26.38% | 26.38% | 26.38% | 27.48% | 27.82% |
| Public | 73.62% | 73.62% | 73.61% | 73.61% | 73.62% | 73.62% | 72.53% | 72.19% |
| No. of shareholders | 7,364 | 7,429 | 7,431 | 7,415 | 7,446 | 7,409 | 7,349 | 7,309 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Beryl Drugs Ltd corporate filings
- The Exchange has received the disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Sudhir SethiInsider Trading / SASTlow impact
Cruxal's analysis: Beryl Drugs Limited has disclosed that its promoter, Mr. Sudhir Sethi, acquired 4,809…
Read the full analysis - The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Sudhir SethiInsider Trading / SASTlow impact
Cruxal's analysis: Beryl Drugs Limited has disclosed that its main promoter, Mr. Sudhir Sethi, acquired…
Read the full analysis - NEWSPAPER PUBLICATION OF UNAUDITED QUARTERLY FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE, 2026Company Updatehigh impact
Cruxal's analysis: Beryl Drugs Limited has reported unaudited financial results for the quarter ended 30…
Read the full analysis - UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE, 2026Resulthigh impact
Cruxal's analysis: Beryl Drugs Limited reported a strong performance for the quarter ended 30 June 2026…
Read the full analysis - OUTCOME OF BOARD MEETINGBoard Meetinglow impact
Cruxal's analysis: Beryl Drugs Limited has formally announced the conclusion of its board meeting held on…
Read the full analysis - Beryl Drugs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/08/2026 ,inter alia, to consider and approve the unaudited financial results ....Board Meetinglow impact
Cruxal's analysis: Beryl Drugs Limited has issued a formal notice for a Board of Directors meeting scheduled…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Track Beryl Drugs Ltd
Cruxal reads every Beryl Drugs Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.